IL108501A - Antibodies and pharmaceutical compositions containing them - Google Patents

Antibodies and pharmaceutical compositions containing them

Info

Publication number
IL108501A
IL108501A IL10850194A IL10850194A IL108501A IL 108501 A IL108501 A IL 108501A IL 10850194 A IL10850194 A IL 10850194A IL 10850194 A IL10850194 A IL 10850194A IL 108501 A IL108501 A IL 108501A
Authority
IL
Israel
Prior art keywords
antibody
bat
cell line
cells
hybridoma cell
Prior art date
Application number
IL10850194A
Other languages
English (en)
Other versions
IL108501A0 (en
Inventor
Britta Hardy
Abraham Novogrodsky
Original Assignee
Mor Research Applic Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mor Research Applic Ltd filed Critical Mor Research Applic Ltd
Priority to IL10850194A priority Critical patent/IL108501A/en
Publication of IL108501A0 publication Critical patent/IL108501A0/xx
Priority to FI963004A priority patent/FI963004A7/fi
Priority to RU96116984/13A priority patent/RU2155190C2/ru
Priority to ES95910891T priority patent/ES2124533T3/es
Priority to CA002182289A priority patent/CA2182289C/en
Priority to AU18686/95A priority patent/AU693526B2/en
Priority to DK95910891T priority patent/DK0742795T3/da
Priority to JP52021095A priority patent/JP3478398B2/ja
Priority to MD96-0296A priority patent/MD1374G2/ro
Priority to SI9530125T priority patent/SI0742795T1/xx
Priority to EE9600107A priority patent/EE03285B1/xx
Priority to DE69504955T priority patent/DE69504955T2/de
Priority to US08/380,857 priority patent/US5897862A/en
Priority to EP95910891A priority patent/EP0742795B1/en
Priority to PCT/US1995/001137 priority patent/WO1995020605A1/en
Priority to CN95192406A priority patent/CN1052733C/zh
Priority to AT95910891T priority patent/ATE171461T1/de
Priority to MX9603080A priority patent/MX9603080A/es
Priority to NO19963168A priority patent/NO317020B1/no
Priority to LT96-115A priority patent/LT4225B/lt
Priority to LVP-96-317A priority patent/LV11624B/en
Publication of IL108501A publication Critical patent/IL108501A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Detergent Compositions (AREA)
IL10850194A 1994-01-31 1994-01-31 Antibodies and pharmaceutical compositions containing them IL108501A (en)

Priority Applications (21)

Application Number Priority Date Filing Date Title
IL10850194A IL108501A (en) 1994-01-31 1994-01-31 Antibodies and pharmaceutical compositions containing them
AT95910891T ATE171461T1 (de) 1994-01-31 1995-01-30 Immunstimulierende monoklonale antikörper
EE9600107A EE03285B1 (et) 1994-01-31 1995-01-30 Immuunsust stimuleerivad monoklonaalsed antikehad
US08/380,857 US5897862A (en) 1994-01-31 1995-01-30 Immuno-stimulatory monoclonal antibodies
ES95910891T ES2124533T3 (es) 1994-01-31 1995-01-30 Anticuerpos monoclonales inmunoestimulantes.
CA002182289A CA2182289C (en) 1994-01-31 1995-01-30 Immuno-stimulatory monoclonal antibodies
AU18686/95A AU693526B2 (en) 1994-01-31 1995-01-30 Immuno-stimulatory monoclonal antibodies
DK95910891T DK0742795T3 (da) 1994-01-31 1995-01-30 Immunstimulerende monoklonale antistoffer
JP52021095A JP3478398B2 (ja) 1994-01-31 1995-01-30 免疫刺激性モノクローナル抗体
MD96-0296A MD1374G2 (ro) 1994-01-31 1995-01-30 Anticorpi monoclonali imunostimulatori, procedeu de obţinere a acestora, linii celulare, metodă de tratare a maladiilor şi compoziţie farmaceutică
SI9530125T SI0742795T1 (en) 1994-01-31 1995-01-30 Immuno-stimulatory monoclonal antibodies
FI963004A FI963004A7 (fi) 1994-01-31 1995-01-30 Vasta-aineen muodostumista kiihottavia monoklonaalivasta-aineita
DE69504955T DE69504955T2 (de) 1994-01-31 1995-01-30 Immunstimulierende monoklonale antikörper
RU96116984/13A RU2155190C2 (ru) 1994-01-31 1995-01-30 Иммуностимуляторные моноклональные антитела
EP95910891A EP0742795B1 (en) 1994-01-31 1995-01-30 Immuno-stimulatory monoclonal antibodies
PCT/US1995/001137 WO1995020605A1 (en) 1994-01-31 1995-01-30 Immuno-stimulatory monoclonal antibodies
CN95192406A CN1052733C (zh) 1994-01-31 1995-01-30 免疫刺激单克隆抗体
NO19963168A NO317020B1 (no) 1994-01-31 1996-07-29 Immunstimulatoriske monoklonale antistoffer
MX9603080A MX9603080A (es) 1994-01-31 1996-07-29 Anticuerpos monoclonales inmuno-estimulantes.
LT96-115A LT4225B (en) 1994-01-31 1996-07-30 Immuno-stimulatory monoclonal antibodies
LVP-96-317A LV11624B (en) 1994-01-31 1996-09-06 Immuno-stimulatory monoclonal antibodies

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IL10850194A IL108501A (en) 1994-01-31 1994-01-31 Antibodies and pharmaceutical compositions containing them

Publications (2)

Publication Number Publication Date
IL108501A0 IL108501A0 (en) 1994-05-30
IL108501A true IL108501A (en) 1998-10-30

Family

ID=11065761

Family Applications (1)

Application Number Title Priority Date Filing Date
IL10850194A IL108501A (en) 1994-01-31 1994-01-31 Antibodies and pharmaceutical compositions containing them

Country Status (20)

Country Link
US (1) US5897862A (lt)
EP (1) EP0742795B1 (lt)
JP (1) JP3478398B2 (lt)
CN (1) CN1052733C (lt)
AT (1) ATE171461T1 (lt)
AU (1) AU693526B2 (lt)
CA (1) CA2182289C (lt)
DE (1) DE69504955T2 (lt)
DK (1) DK0742795T3 (lt)
EE (1) EE03285B1 (lt)
ES (1) ES2124533T3 (lt)
FI (1) FI963004A7 (lt)
IL (1) IL108501A (lt)
LT (1) LT4225B (lt)
LV (1) LV11624B (lt)
MD (1) MD1374G2 (lt)
MX (1) MX9603080A (lt)
NO (1) NO317020B1 (lt)
RU (1) RU2155190C2 (lt)
WO (1) WO1995020605A1 (lt)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2145634C1 (ru) * 1998-03-12 2000-02-20 Булычева Татьяна Ивановна Штамм культивируемых клеток мышиной гибридомы, используемый для получения моноклональных антител к ядрышковому антигену, ассоциированному с клеточной пролиферацией
IL129299A0 (en) 1999-03-31 2000-02-17 Mor Research Applic Ltd Monoclonal antibodies antigens and diagnosis of malignant diseases
RU2192888C1 (ru) * 2001-02-15 2002-11-20 Эпштейн Олег Ильич Лекарственное средство и способ лечения патологического синдрома
CN1294148C (zh) * 2001-04-11 2007-01-10 中国科学院遗传与发育生物学研究所 环状单链三特异抗体
IL145926A0 (en) 2001-10-15 2002-07-25 Mor Research Applic Ltd Peptide epitopes of mimotopes useful in immunomodulation
IL149820A0 (en) 2002-05-23 2002-11-10 Curetech Ltd Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency
PT1537878E (pt) 2002-07-03 2010-11-18 Ono Pharmaceutical Co Composições de imunopotenciação
DE10311248A1 (de) * 2003-03-14 2004-09-30 Müller-Hermelink, Hans Konrad, Prof. Dr. Humaner monoklonaler Antikörper
BRPI0412138B8 (pt) * 2003-07-02 2021-05-25 Innate Pharma método de selecionar um anticorpo monoclonal, método de selecionar um anticorpo monoclonal ou seu fragmento de ligação em antígeno, método de detectar a presença de células nk, e, método de purificar de uma amostra células nk
US20090123413A1 (en) * 2004-08-23 2009-05-14 Britta Hardy Use of bat monoclonal antibody for immunotherapy
CN103059138B (zh) 2005-05-09 2015-10-28 小野药品工业株式会社 程序性死亡-1(pd-1)的人单克隆抗体及使用抗pd-1抗体来治疗癌症的方法
WO2007005874A2 (en) 2005-07-01 2007-01-11 Medarex, Inc. Human monoclonal antibodies to programmed death ligand 1 (pd-l1)
EP3222634A1 (en) 2007-06-18 2017-09-27 Merck Sharp & Dohme B.V. Antibodies to human programmed death receptor pd-1
PT2242773T (pt) * 2008-02-11 2017-09-15 Cure Tech Ltd Anticorpos monoclonais para o tratamento de tumores
MD3972C2 (ro) * 2009-03-11 2010-07-31 Ион МЕРЕУЦЭ Remediu şi metodă de tratament al stărilor precanceroase
WO2013014668A1 (en) 2011-07-24 2013-01-31 Curetech Ltd. Variants of humanized immunomodulatory monoclonal antibodies
US10570204B2 (en) 2013-09-26 2020-02-25 The Medical College Of Wisconsin, Inc. Methods for treating hematologic cancers
US9580504B1 (en) 2013-11-07 2017-02-28 Curetech Ltd. Pidilizumab monoclonal antibody therapy following stem cell transplantation
US9683048B2 (en) 2014-01-24 2017-06-20 Novartis Ag Antibody molecules to PD-1 and uses thereof
ME03489B (me) 2014-01-31 2020-01-20 Novartis Ag Molekuli antitijela na tim-3 i njihove upotrebe
JP6576962B2 (ja) 2014-03-14 2019-09-18 ノバルティス アーゲー Ｌａｇ−３に対する抗体分子およびその使用
TWI693232B (zh) 2014-06-26 2020-05-11 美商宏觀基因股份有限公司 與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法
EP3191126B1 (en) 2014-09-13 2020-05-13 Novartis AG Combination therapies of alk inhibitors
TWI773646B (zh) 2015-06-08 2022-08-11 美商宏觀基因股份有限公司 結合lag-3的分子和其使用方法
MA58293B1 (fr) 2015-07-30 2024-11-29 Macrogenics, Inc. Molécules de liaison pd-1 et leurs procédés d'utilisation
KR20220131277A (ko) 2015-09-01 2022-09-27 아게누스 인코포레이티드 항-pd-1 항체 및 이를 이용하는 방법
US10428145B2 (en) 2015-09-29 2019-10-01 Celgene Corporation PD-1 binding proteins and methods of use thereof
HUE057837T2 (hu) 2015-11-03 2022-06-28 Janssen Biotech Inc PD-1-et specifikusan kötõ ellenanyagok és alkalmazásaik
CN108367069B (zh) 2015-12-14 2022-08-23 宏观基因有限公司 对于pd-1和ctla-4具有免疫反应性的双特异性分子及其使用方法
KR102379464B1 (ko) 2016-06-20 2022-03-29 키맵 리미티드 항-pd-l1 항체
KR102257154B1 (ko) 2016-09-19 2021-05-28 셀진 코포레이션 Pd-1 결합 단백질을 사용하는 면역 질환의 치료 방법
EP3515943A4 (en) 2016-09-19 2020-05-06 Celgene Corporation METHODS OF TREATING VITILIGO WITH PD-1 BINDING PROTEINS
PE20190921A1 (es) 2016-12-07 2019-06-26 Agenus Inc Anticuerpos y metodos de su utilizacion
US12398209B2 (en) 2018-01-22 2025-08-26 Janssen Biotech, Inc. Methods of treating cancers with antagonistic anti-PD-1 antibodies
GB202107994D0 (en) 2021-06-04 2021-07-21 Kymab Ltd Treatment of cancer
IL322179A (en) 2023-01-30 2025-09-01 Kymab Ltd Antibodies

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5182368A (en) * 1986-06-13 1993-01-26 Ledbetter Jeffrey A Ligands and methods for augmenting B-cell proliferation

Also Published As

Publication number Publication date
EP0742795A1 (en) 1996-11-20
MX9603080A (es) 1998-01-31
CN1145077A (zh) 1997-03-12
EP0742795B1 (en) 1998-09-23
FI963004L (fi) 1996-09-27
IL108501A0 (en) 1994-05-30
FI963004A7 (fi) 1996-09-27
CA2182289A1 (en) 1995-08-03
MD1374F2 (en) 1999-12-31
CA2182289C (en) 2003-10-21
NO963168L (no) 1996-09-27
US5897862A (en) 1999-04-27
ES2124533T3 (es) 1999-02-01
LT96115A (en) 1997-05-26
AU1868695A (en) 1995-08-15
NO963168D0 (no) 1996-07-29
DE69504955T2 (de) 1999-05-27
DE69504955D1 (de) 1998-10-29
JPH09508390A (ja) 1997-08-26
LT4225B (en) 1997-10-27
LV11624B (en) 1997-06-20
AU693526B2 (en) 1998-07-02
CN1052733C (zh) 2000-05-24
MD1374G2 (ro) 2000-09-30
RU2155190C2 (ru) 2000-08-27
ATE171461T1 (de) 1998-10-15
NO317020B1 (no) 2004-07-26
JP3478398B2 (ja) 2003-12-15
LV11624A (en) 1996-12-20
EE03285B1 (et) 2000-08-15
FI963004A0 (fi) 1996-07-29
WO1995020605A1 (en) 1995-08-03
DK0742795T3 (da) 1999-06-14

Similar Documents

Publication Publication Date Title
US5897862A (en) Immuno-stimulatory monoclonal antibodies
WO1995020605A9 (en) Immuno-stimulatory monoclonal antibodies
MXPA96003080A (en) Monoclonal antibodies immuno-estimulan
US7794710B2 (en) Methods of enhancing T cell responsiveness
ES2579277T3 (es) Utilización combinada de un agente de bloqueo CTLA-4 y una terapia linfotóxica en el tratamiento de tumores
Seon et al. Long-lasting complete inhibition of human solid tumors in SCID mice by targeting endothelial cells of tumor vasculature with antihuman endoglin immunotoxin.
US20210214436A1 (en) Multi-specific binding proteins and improvements thereon
US6852320B2 (en) T cell inhibitory receptor compositions and uses thereof
US6197298B1 (en) Modified binding molecules specific for T lymphocytes and their use as in vivo immune modulators in animals
AU2002219229B2 (en) Means for the diagnosis and therapy of CTCL
KR19990022650A (ko) 사람 ｂ7.1 및/또는 ｂ7.2 영장류화된 형태에 특이적인 원숭이 단일클론성 항체 및 이의 약제학적 조성물
CA2179196A1 (en) Method of preventing or treating disease characterized by neoplastic cells expressing cd40
AU2015300006B2 (en) Therapeutic agent for cancer which comprises combination of IL-18 and molecule-targeting antibody
CN109195988A (zh) 用于增强超抗原介导的癌症免疫疗法效力的方法和组合物
US10344073B2 (en) Cell compositions and methods for cancer therapy
KR20110085038A (ko) 항 ｃｄ137-항체 및 독소 결합물을 이용한 ｃｄ137 양성세포의 제거방법
Hardy et al. A monoclonal antibody against a human B lymphoblastoid cell line induces tumor regression in mice
Saha et al. CTLA4 (CD152) modulates the Th subset response and alters the course of experimental Leishmania major infection
JPH01126558A (ja) 抗体依存性細胞性細胞毒性の測定方法
Wang et al. Targeting solid tumors via T cell receptor complementarity-determining region 3δ in an engineered antibody
Kudo et al. Specific targeting immunotherapy of cancer with bispecific antibodies
US20240293546A1 (en) D2c7 egfr and egfr viii bi-specific chimeric antigen receptor constructs and methods of making and using same
Hollingworth The manipulation of cellular immunity by monoclonal antibodies in cancer patients
Olson et al. Enhancing Anti-Tumor Activity Against Glioblastoma and Neuroblastoma by Retargeting T Cells with OKT3 X Anti-EGFR
Mukherjee et al. Therapeutic Efficacy of Muci-Specific Cytotoxic T Lymphocytes and CD137 Co-Stimulation in a Spontaneous Mammary Cancer Model

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
NP Permission for amending the patent specification granted (section 66, patents law 1967)
KB Patent renewed
KB Patent renewed
KB Patent renewed
KB Patent renewed
EXP Patent expired